Lexeo Therapeutics宣布，其针对PKP2致心律失常性心肌病（PKP2 ACM）的候选药物LX2020，已获得美国食品药品监督管理局（FDA）授予的再生医学先进疗法（RMAT）认定。这一里程碑式的进展，为该创新疗法在罕见心脏病领域的研发注入了强劲动力。
Lexeo Therapeutics宣布，其针对PKP2致心律失常性心肌病（PKP2 ACM）的候选药物LX2020，已获得美国食品药品监督管理局（FDA）授予的再生医学先进疗法（RMAT）认定。这一里程碑式的进展，为该创新疗法在罕见心脏病领域的研发注入了强劲动力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.